Scarica l'app Stockscreener
117.85
0.38%
-0.45
Dopo l'orario di chiusura:
118.20
0.35
+0.30%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GILD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Gilead Sciences Inc Borsa (GILD) Ultime notizie
Gilead Sciences CFO Dickinson sells $295k in shares - Investing.com
Gilead Sciences’ (GILD) CCO Mercier sells $354k in stock - Investing.com
Kite puts $1.6B on the line to pair up with China’s Pregene for another in vivo CAR-T deal - Fierce Biotech
RBC Warns Gilead (GILD) Faces Risk from Trump’s Price Cut Target - MSN
IgG4 – Related diseases Market: Epidemiology, Therapies, Companies, DelveInsight | Roche, AbbVie, Gilead Sciences, Takeda Pharmaceutical Company - The Globe and Mail
Is this a good reentry point in Gilead Sciences Inc.2025 Trading Volume Trends & Community Trade Idea Sharing - newser.com
Gilead Foundation Launches STEM Careers Partnership with Boys & Girls Clubs of America - Boys & Girls Clubs of America
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Gilead presents new HIV research data at EACS 2025 – driving scientific innovation in treatment and prevention - European AIDS Treatment Group
Gilead to present data on potential first weekly oral treatment for HIV - Clinical Trials Arena
Merck's New HIV Treatment Works As Well As Top Drug In Late Trials - Benzinga
Gilead highlights HIV pipeline at European AIDS Conference - The Pharma Letter
Sjogren’s Syndrome Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | Gilead Sciences, Incyte Corp, Novartis, GlaxoSmithKline, Janssen Research & Development, LLC - Barchart.com
GSK touts study showing acceptability edge for its long-acting PrEP drug amid Gilead showdown - Fierce Pharma
ViiV says its HIV PrEP therapy outperformed Gilead’s lenacapavir in early-stage trial - Seeking Alpha
Gilead Presents New HIV Research Data at EACS 2025 – Driving Scientific Innovation in Treatment and Prevention - BioSpace
Gilead (GILD) Showcases Advances in HIV Research at European AIDS Conference - GuruFocus
Gilead presents new HIV research data at European AIDS Conference - StreetInsider
Chinese Research Org. Says Gilead Infringed COVID Patent - Law360
Gilead and Arcus see survival boost with gastric cancer combo - The Pharma Letter
Gilead Sciences/Arcus Biosciences' Investigational Cancer Drug Shows Overall Survival Of Around 27 Months - Benzinga
Gilead to present promising data for Trodelvy in breast cancer at ESMO - Investing.com
Gilead to present Trodelvy breast cancer data at ESMO 2025 - StreetInsider
Gilead, Coinbase, Rocket Lab And A Tech Stock On CNBC's 'Final Trades' - Benzinga
Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care With New Data at ESMO 2025 - Business Wire
Yousif Capital Management LLC Sells 2,855 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Survival data boost prospects for Gilead, Arcus TIGIT drug in gastric cancer - firstwordpharma.com
ADAPT: Accelerating Disability Awareness & Progress Together - Gilead Sciences
OFI Invest Asset Management Sells 86,817 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Transcendent Capital Group LLC Invests $432,000 in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Position Boosted by Sivik Global Healthcare LLC - MarketBeat
Natural Investments LLC Has $317,000 Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Lmcg Investments LLC Has $1.97 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
How Investors Are Reacting To Gilead Sciences (GILD) Expanding HIV Drug Access and Delaying Generics - Sahm
How Investors Are Reacting To Gilead Sciences (GILD) Extending Biktarvy Exclusivity and Advancing HIV, Oncology Pipeline - Yahoo Finance
How the Story Behind Gilead Is Evolving in Light of Key Analyst and Industry Updates - Yahoo Finance
Conning Inc. Increases Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Fourpath Capital Management LLC Reduces Stake in Gilead Sciences, Inc. $GILD - MarketBeat
3Chopt Investment Partners LLC Acquires 3,318 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by Aberdeen Group plc - MarketBeat
Gilead Sciences (NASDAQ:GILD) Stock Unloaded Rep. Val T. Hoyle - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Gilead: Incorporating Longer Biktarvy Runway - Morningstar
Gilead's HIV Portfolio Has a Long Runway and Supports a Wide Moat - Morningstar
Cantor Fitzgerald Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price - MarketBeat
Blair William & Co. IL Decreases Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Trifecta Capital Advisors LLC Has $339,000 Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
TFR Capital LLC. Makes New $283,000 Investment in Gilead Sciences, Inc. $GILD - MarketBeat
Callan Family Office LLC Purchases 63,300 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Tectonic Advisors LLC Increases Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Maryland State Retirement & Pension System Increases Position in Gilead Sciences, Inc. $GILD - MarketBeat
US Bancorp DE Sells 22,670 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Vontobel Holding Ltd. Lowers Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Can Gilead Sciences Inc. hit a new high this monthWeekly Investment Report & Fast Moving Trade Plans - newser.com
Real time social sentiment graph for Gilead Sciences Inc.July 2025 Setups & Weekly Breakout Stock Alerts - newser.com
Gilead Sciences to Release Third Quarter 2025 Financial Results on Thursday, October 30, 2025 - BioSpace
"Taking possibility back" across oncology’s toughest frontiers - statnews.com
Gilead Sciences To Release Third Quarter 2025 Financial Results On Thursday, October 30, 2025 - TradingView
RBC Capital Reaffirms Their Hold Rating on Gilead Sciences (GILD) - The Globe and Mail
Gilead blocks HIV drug generics for more than 10 years - Life Sciences Intellectual Property Review
A Look Inside Gilead's Inflammation Pipeline - Gilead Sciences
Cantor Fitzgerald Adjusts PT on Gilead Sciences to $135 From $129, Maintains Overweight Rating - MarketScreener
Can Gilead Sciences Inc. stock deliver consistent earnings growthMarket Trend Summary & Real-Time Market Sentiment Reports - newser.com
Fluent Financial LLC Raises Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Kingswood Wealth Advisors LLC Reduces Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (NASDAQ:GILD) Given "Buy (B)" Rating at Weiss Ratings - MarketBeat
Citigroup Maintains Gilead Sciences (GILD) Buy Recommendation - Nasdaq
Gilead Sciences Rallies After Trump Partnership News Is the Growth Story Just Beginning - Yahoo Finance
GILD: Citigroup Raises Price Target for Gilead Sciences Amid Buy Rating | GILD Stock News - GuruFocus
Greed Is a Hell of a Drug - Truthdig
RBC Capital raises Gilead Sciences stock price target to $100 on Yeztugo launch - Investing.com
Royal Bank Of Canada Increases Gilead Sciences (NASDAQ:GILD) Price Target to $100.00 - MarketBeat
Gilead Sciences (NASDAQ:GILD) Price Target Raised to $135.00 at Citigroup - MarketBeat
Citigroup Adjusts Price Target on Gilead Sciences to $135 From $125, Maintains Buy Rating - MarketScreener
RBC Lifts Price Target on Gilead Sciences to $100 From $98, Keeps Sector Perform Rating - MarketScreener
Prime Capital Investment Advisors LLC Decreases Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
0.66%
2.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):